



*JFL* /  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Wadih Arap and Renata Pasqualini

Serial No.: 10/784,537

Filed: February 23 ,2004

For: AMINOPEPTIDASE A (APA)  
TARGETING PEPTIDES FOR THE  
TREATMENT OF CANCER

Group Art Unit: 1648

Examiner: Bao Q. Li

Atty. Dkt. No.: UTSC:872US

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
November 6, 2006	<i>[Signature]</i> Date David L. Parker

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**MS AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. § 1.97(g), (h), this Supplemental Information Disclosure

Statement is not to be construed as a representation that a search has been made, and is not to be

11/09/2006 RFEKADU1 00000065 10784537

01 FC:1806


180.00 OP

25714614.1

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed. If an appropriate check has not been enclosed, or if it is insufficient, the Commissioner is authorized to deduct the appropriate fee from Fulbright & Jaworski Account No.: 50-1212/UTSC:872US.


Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,  


David L. Parker  
Reg. No. 32,165  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: November 6, 2006



Total Number of Pages in this Submission : \_\_\_\_\_

<b>Application Number:</b>	10/784,537
<b>Filing Date:</b>	February 23, 2004
<b>First Named Inventor:</b>	Wadih Arap
<b>Art Unit:</b>	1648
<b>Examiner Name:</b>	Bao Q Li
<b>Attorney Docket Number:</b>	UTSC:872US

**ENCLOSURES (check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input checked="" type="checkbox"/> Information Disclosure Statement <input checked="" type="checkbox"/> Form PTO-1449 <input checked="" type="checkbox"/> References B19-B23; C215-C230 <input type="checkbox"/> Foreign Search Report  <input type="checkbox"/> Certified Copy of Priority Documents  <input type="checkbox"/> Reply to Missing Parts/ Requirements <input type="checkbox"/> Reply to Missing Parts/Requirements <input type="checkbox"/> Declaration(s) <input type="checkbox"/> Copy of Notice of Missing Parts/Requirements	<input type="checkbox"/> Drawings(s) _____  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Statement under 37 CFR §3.73(b) <input type="checkbox"/> Designation of Patent Practitioners  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below) <ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> Check in the amount of \$180.00</li> <li><input checked="" type="checkbox"/> Authorized to be charged to deposit account if check insufficient or inadvertently omitted Deposit account number: <u>50-1212/UTSC:872US</u></li> <li><input type="checkbox"/> Sequence Statement</li> <li><input type="checkbox"/> Paper Copy of Sequence Listing</li> <li><input type="checkbox"/> Computer Readable Form (CRF)</li> <li><input checked="" type="checkbox"/> Postcard</li> <li><input type="checkbox"/> _____</li> <li><input type="checkbox"/> _____</li> </ul>
Remarks:		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	Fulbright & Jaworski L.L.P.	Customer Number	32425
Signature			
Printed Name	David L. Parker	Reg. No.	32,165
Date	November 6, 2006		

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or Printed Name	David L. Parker	Date	November 6, 2006

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:872US

10/784,537

**List of Patents and Publications for Applicant's****INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

**Applicant**

Wadih Arap

Renata Pasqualini

**Filing Date:**

February 23, 2004

**Group:**

1648

**U.S. Patent Documents**

See Page 1

**Foreign Patent Documents**

See Page 1

**Other Art**

See Page 1-3

**U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A40	4,931,053	06/05/90	L'Esperance, Jr.	606	2	01/27/88
	A41	5,259,380	11/09/93	Mendes <i>et al.</i>	607	115	11/15/90
	A42	5,464,436	11/07/95	Smith	607	89	04/28/94
	A43	5,585,277	12/17/96	Bowie <i>et al.</i>	436	518	03/21/95
	A44	6,057,098	05/02/00	Buechler <i>et al.</i>	435	6	04/04/97
	A45	6,184,973	02/06/01	Baer <i>et al.</i>	356	36	04/10/98
	A46	6,215,550	04/10/01	Baer <i>et al.</i>	356	36	07/23/98
	A47	6,271,196	08/07/01	O'Brien	514	2	03/05/96

**Foreign Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B19	JP 4026631	01/29/92	Japan	Japanese (English Abstract)
	B20	WO 00/14215	03/16/00	WIPO	German (English Abstract)
	B21	WO 02/02055	01/10/02	WIPO	English
	B22	WO 02/20722	03/14/02	WIPO	English
	B23	WO 94/28424	12/08/94	WIPO	English

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C215	Alonso and Maroto, "Plants as 'chemical factories' for the production of polyunsaturated fatty acids," <i>Biotechnology Advances</i> , 18:481-497, 200.
	C216	Arap <i>et al.</i> , "Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands," <i>Cancer Cell</i> , 6:275-284, 2004.

25714526.1

**EXAMINER:****DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
<b>List of Patents and Publications for Applicant's</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>  (Use several sheets if necessary)		<b>Applicant</b> <b>Wadih Arap</b> <b>Renata Pasqualini</b>	
		Filing Date: February 23, 2004	Group: 1648
<b>U.S. Patent Documents</b> <i>See Page 1</i>	<b>Foreign Patent Documents</b> <i>See Page 1</i>	<b>Other Art</b> <i>See Page 1-3</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C217	De Rosa <i>et al.</i> , "Poly(lactide-co-glycolide) microspheres for the controlled release of oligonucleotide/polyethylenimine complexes," <i>J Pharm Sci</i> , 91(3):790-799, 2002.
	C218	Fairbrother <i>et al.</i> , "Novel Peptides Selected to Bind Vascular Endothelial Growth Factor Target Receptor-Binding Site," <i>Biochemistry</i> , 37:17754-17764, 1998.
	C219	Gong <i>et al.</i> , "Prostrate-specific membrane antigen (PMSA)-specific monoclonal antibodies in the treatment of prostate and other cancers," <i>Cancer and Metastasis Reviews</i> , 18:483-490, 1999.
	C220	Johnson <i>et al.</i> , In: <i>Biotechnology and Pharmacy</i> , Pezzuto <i>et al.</i> eds., Chapman and Hall, NY, 1993.
	C221	Kolonin <i>et al.</i> , "Reversal of obesity by targeted ablation of adipose tissue," <i>Nature Medicine</i> , 10: 625-632, 2004.
	C222	Mintz <i>et al.</i> , "Fingerprinting the circulating repertoire of antibodies from cancer patients," <i>Nature Biotechnology</i> , 21:57-63, 2003.
	C223	Napier and Michaelson, "Genomic and Functional Characterization of Polyunsaturated Fatty Acid Biosynthesis in <i>Caenorhabditis elegans</i> ," <i>Lipids</i> , 36:761-766, 2001.
	C224	Nicklin <i>et al.</i> , "Selective argeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display," <i>Circulation</i> , 102:231-237, 2000.
	C225	Oike <i>et al.</i> , "Angiopoietin-related growth factors antagonizes obesity and insulin resistence," <i>Nature Medicine</i> , 11:400-408, 2005.
	C226	Ozata <i>et al.</i> , "Human Leptin Deficiency caused by a missense Mutation: Multiple Endocrine Defects, Decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defec," <i>Jounral of Clinical Endocrinology and Metabolism</i> , 84:3686-3695, 1999.
	C227	Polgren <i>et al.</i> , "Identification of muscle homing sequences by using phage display libraries of peptides," <i>Tumor Biology</i> , 18:77, 1997.
	C228	Schindler, "Select, microdissect, adneject." <i>Nature Biotechnology</i> , 16:719-720, 1998.

25714526.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
<b>List of Patents and Publications for Applicant's</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <small>(Use several sheets if necessary)</small>		<b>Applicant</b> <b>Wadih Arap</b> <b>Renata Pasqualini</b>	
		Filing Date: February 23, 2004	Group: 1648
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page I-3</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C229	Wang <i>et al.</i> , "Rapid antibody responses by low-dose, single-step, dendritic cell-target immunization," <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 97:847-852, 2000.
	C230	Yao <i>et al.</i> "Targeting pancreatic islets with phage display assisted by laser pressure catapult microdissection," <i>The American Journal of Pathology</i> , 166:625-636, 2005.

25714526.1

EXAMINER:	DATE CONSIDERED:
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	